RxDoctor Payments Data

Vera Bocoun, MD

Rheumatology · Wausau, WINPI 1235233560

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,799 of the $3,421 with a category attached, or 81.8%. 13 manufacturers reported payments, led by AbbVie at 29.2% of the total. Reporting peaked in 2022 at $1,214 and has fallen 92.4% since, to $92 in 2025.

$3,421in general payments, 2019–2025

Across 44 payments — averaging $77.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$999
  • Johnson & Johnson$677
  • Amgen$406
  • Janssen Scientific Affairs, LLC$250
  • Aurinia Pharma U.S., Inc.$219
  • AstraZeneca$145
  • plus $725 from 7 others

What the payments were for

  • Consulting fees$56016%
  • Food & beverage$2,79982%
  • Education$632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,421 in reported general payments places this provider in the 75th percentile of 120 rheumatology providers in Wisconsin.

See all rheumatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$25,518
Medicare patients
165
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib82$590,231
Humira(Cf) PenAdalimumab49$450,127
Enbrel SureclickEtanercept26$190,916
Humira PenAdalimumab15$100,854
KevzaraSarilumab11$47,249
MethotrexateMethotrexate Sodium301$6,124
Hydroxychloroquine Sulfate181$5,722
Leflunomide65$3,623
Colchicine31$2,972
Prednisone317$2,383
Mycophenolate Mofetil23$2,009
Celecoxib46$1,194
Sulfasalazine42$1,178
Methylprednisolone19$952
Oxaprozin13$747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$999$590,23182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 120 rheumatology providers in Wisconsin.

Other rheumatology in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →